Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib versus investigator's choice immunotherapy or observation after resection in KRAS G12C-positive stage II-III non-small cell lung cancer
2025-524263-21-01Phase 3Authorised
- Sponsor
- Roche
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Divarasib with Investigator's choice immunotherapy or observation (2 arms). Primary endpoint: Disease-free survival. Planned start Sep 2026; status: authorised.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-524263-21-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524263-21-01.